DLL3 Targeting Chimeric Antigen Receptors and Binding Agents

Sat, 18 Apr 2026 03:29:10 +0000
Intellectual Property

EPO published patent application EP3930744A1 by Allogene Therapeutics Inc. and Pfizer Inc. for DLL3 targeting chimeric antigen receptors (CARs) and binding agents. The application classified under A61K 39/00, A61P 35/00, and C07K 16/28 covers therapeutic compositions targeting DLL3 for cancer treatment. The patent designates 31 European states including Germany, France, the United Kingdom, Italy, Spain, and other EU member states.